Stereotaxis shares surge 10.17% premarket following FDA approval of MAGiC magnetic ablation catheter for complex cardiac arrhythmia treatment.

Stereotaxis surged 10.17% in premarket trading following the U.S. Food and Drug Administration (FDA) approval of its MAGiC Magnetic Interventional Ablation Catheter. The robotic, magnetically navigated device is designed to treat complex heart arrhythmias in patients with congenital heart disease, offering enhanced precision and maneuverability compared to traditional catheters. The approval, hailed as a "significant milestone" by executives and clinicians, expands access to minimally invasive cardiac ablation therapy for underserved populations and reinforces Stereotaxis’ leadership in surgical robotics. The news aligns with the company’s strategic focus on advancing robotic electrophysiology solutions, with analysts and medical experts emphasizing its potential to drive adoption and improve patient outcomes. This regulatory breakthrough, coupled with recent analyst coverage upgrading the stock, directly fueled the premarket rally.